We are investigating Innate Pharma S.A. (IPHA) (“Innate” or the “Company”) for potential violations of the federal securities laws.
On January 9, 2020, Innate announced its decision “to suspend enrollment of new patients” in its TELLOMAK Phase II trial, evaluating the efficacy and safety of lacutamab (IPH4102) in patients with advanced T-cell lymphomas. Innate cited “ongoing discussions with regulatory authorities regarding Good Manufacturing Practice (GMP) deficiencies at the Company’s manufacturing subcontractor site that manages the fill and finish operations of the lacutamab clinical vials.” On this news, Innate’s American depositary receipt price fell sharply during intraday trading on January 9, 2020.